1. Simvastatin (Zocor) in combination with paclitaxel (Taxol) is well tolerated and associated with significantly reduced disease progression compared to ...
![Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/Taxus_stent_FDA-e1607803635904-350x250.jpg)
1. All-cause mortality and reduction in major amputations were similar between groups. 2. The rate of target vessel reintervention was ...
1. Progression-free survival was significantly greater in retifanlimab compared to placebo. 2. Serious and grade 3 or more adverse events ...
1. Progression-free and overall survival were greater in relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone. 2. The rate of adverse ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated ...
1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated ...
Click to read this study in the Journal of Clinical Oncology.
